A miR-18a-RUNX1-ZO-1 regulatory network also increases the permeability of the blood-tumor barrier (BTB), thereby providing novel potential targets for drug transportation across the BTB as an attractive strategy for glioma treatment [119]. Here, RUNX1 is linked to glioma.